T he health benefits of a balanced diet rich in fiber are well established, however, understanding of mechanisms underlying these benefits has only recently come to light with appreciation of the relationship between ingested food, the gut microbiome and health and well-being 1 . In the case of dietary fiber, fermentation of poorly digested carbohydrates by the gut microbiota produces prodigious amounts of SCFAs, particularly acetate and propionate 2 . These SCFAs, in addition to acting as an energy source, also have direct biological activities by acting in a hormonelike fashion through specific GPCRs 3-5 . The physiological roles of the two best characterized SCFA-activated GPCRs, FFA2 and FFA3 (previously known as GPR41 and GPR43 3 ), however, are challenging to define as the potency of SCFAs is both low and similar between these two subtypes. Moreover, pharmacological tools for these receptors are limited and not broadly available 6,7 and the only described FFA2 antagonists are 'human specific' and not effective at rodent orthologs [6] [7] [8] . Despite this, there is great interest in the potential therapeutic use of targeting this receptor class and the FFA2 antagonist GLPG0974 ((4-[[1-(benzo[b]thiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid) has been assessed in 'first-in-man' studies designed to treat ulcerative colitis 9 . To address the physiological role of FFA2 we have adopted a chemogenetic approach pioneered largely using muscarinic acetylcholine receptors. In this approach, mutations in the orthosteric binding site are introduced that prevent receptor activation by endogenous agonists but instead allows for activation by otherwise inert chemical ligands. Such mutant receptors, called designer receptors exclusively activated by designer drugs (DREADDs) have been widely used to probe signaling pathways that underlie both central and peripheral responses [10] [11] [12] [13] [14] [15] . Here, we have taken an alternative approach employing a novel FFA2-DREADD 16 knocked into the gene locus of the wild-type receptor to generate a strain of mice that would mimic an FFA2-receptor knockout strain because the DREADD receptor is predicted to be unresponsive to endogenous SCFAs. However, unlike a gene knockout, phenotypic and functional deficits observed in the FFA2-DREADD-knock-in mice should, theoretically, be rescued by a FFA2-DREADD specific ligand, in this case sorbic acid (SA), which exclusively activates the DREADD receptor
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3 ), however, are challenging to define as the potency of SCFAs is both low and similar between these two subtypes. Moreover, pharmacological tools for these receptors are limited and not broadly available 6, 7 and the only described FFA2 antagonists are 'human specific' and not effective at rodent orthologs [6] [7] [8] . Despite this, there is great interest in the potential therapeutic use of targeting this receptor class and the FFA2 antagonist GLPG0974 ((4-[ [1-(benzo[b] thiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid) has been assessed in 'first-in-man' studies designed to treat ulcerative colitis 9 . To address the physiological role of FFA2 we have adopted a chemogenetic approach pioneered largely using muscarinic acetylcholine receptors. In this approach, mutations in the orthosteric binding site are introduced that prevent receptor activation by endogenous agonists but instead allows for activation by otherwise inert chemical ligands. Such mutant receptors, called designer receptors exclusively activated by designer drugs (DREADDs) have been widely used to probe signaling pathways that underlie both central and peripheral responses [10] [11] [12] [13] [14] [15] . Here, we have taken an alternative approach employing a novel FFA2-DREADD 16 knocked into the gene locus of the wild-type receptor to generate a strain of mice that would mimic an FFA2-receptor knockout strain because the DREADD receptor is predicted to be unresponsive to endogenous SCFAs. However, unlike a gene knockout, phenotypic and functional deficits observed in the FFA2-DREADD-knock-in mice should, theoretically, be rescued by a FFA2-DREADD specific ligand, in this case sorbic acid (SA), which exclusively activates the DREADD receptor 16 . Previously, we generated a DREADD variant of human (h) FFA2 16 by substitution of two amino acids, located in the fourth and sixth transmembrane regions (Cys4.57Gly and His6.55Gln, position numbers as defined by the Ballesteros and Weinstein numbering system 17 ). In so doing, we took advantage of the observed variation in the chain length of fatty acids that act as agonists at certain species orthologs of FFA2 and linked this with homology modeling and mutagenesis to infer potentially important roles for these two residues 16 . The hFFA2-DREADD variant no longer responded effectively to the SCFAs acetate and propionate but, rather, could be activated by a number of other ligands, including SA, which had no effect at either the wild-type receptor or at FFA3 16 . The hFFA2-DREADD was not only activated by SA but, as shown here, is antagonized effectively by a pair of chemically distinct, human ortholog-specific, FFA2 antagonists 8, [18] [19] [20] . By employing these tools here we tested the hypothesis that a DREADD-knock-in mouse strain would induce phenotypic deficits that mimicked a knockout strain and that this deficit might be rescued by a DREADD ligand. Furthermore, we tested if the DREADD ligand response might be blocked by antagonists that are only active at the species ortholog from which the DREADD was derived. Thus, we report here that by using FFA2 as an exemplar receptor we were able to employ hFFA2-DREADD to probe the physiological role of FFA2 in the gut and white adipose tissue and also provide evidence Chemogenetics defines receptor-mediated functions of short chain free fatty acids Daniele Bolognini 1 . This biosensor is based on the competition between Gα and GRK2 for interaction with Gβγ on over-expression of each individual unlabeled Gα subunit. The separation of Gβγ from the Gα subunit on receptor activation produces an increase in BRET between GRK2-GFP 10 and RlucII-Gγ5. Following co-transfection of HEK293 cells expressing the BRET biosensors with either hFFA2 or hFFA2-DREADD and each of 13 distinct G protein α subunits addition of C3 to cells expressing hFFA2 resulted in enhanced BRET signal in the presence of all the G protein α subunits tested, except for Gα s (Fig. 1a) . The magnitude of the enhanced BRET signal varied between individual G protein α subunits but the wide-ranging capacity of hFFA2 to interact with different G proteins confirmed that agonist-activated hFFA2 can be pleiotropic in activation of G protein subtypes 8, 21 . In cells expressing hFFA2-DREADD, addition of SA resulted in an entirely equivalent profile of G protein interaction capacity and selectivity (Fig. 1b) . Thus, despite engineering the orthosteric binding site to generate a DREADD variant receptor, this did not result in altered canonical, G-protein-mediated signal transduction potential in response to the DREADD specific agonist. These studies established that, when acting at the hFFA2-DREADD receptor, SA is able to produce the same and full panoply of G protein interactions as when C3 binds to wild-type FFA2.
To extend these comparisons we employed a second set of biosensors that instead directly sense separation induced by receptor activation between a G protein α subunit tagged with Renilla Percentage inhibition of cAMP production luciferase and the G protein γ1 subunit tagged with the fluorescent protein GFP 10 . When co-expressed alongside wild-type hFFA2, C3 promoted a reduction in BRET signal for the α subunit of each of G q , G i1 and G 13 , but once again not for G s ( Supplementary  Fig. 1a ). The same was true for SA when this sensor pairing was coexpressed with hFFA2-DREADD ( Supplementary Fig. 1b ). Parallel studies using the M 3 muscarinic acetylcholine receptor showed the agonist carbachol only caused activation of G q ( Supplementary  Fig. 1c ) and indicated that the broad range of G proteins activated by the hFFA2 and hFFA2-DREADD receptors is not an artifact related to the assay biosensors employed.
We next investigated the signaling of these receptors specifically through G i and G q/11 , respectively, in cAMP and inositol monophosphate regulation assays that reflect directly activation of these G proteins (Fig. 1c-f ). As expected, at hFFA2 inhibition of cAMP and accumulation of inositol monophosphates was effectively induced by the endogenous SCFA C3, whereas SA showed essentially no activity (Fig. 1c,e) . In contrast, at hFFA2-DREADD SA produced potent regulation of both cAMP and inositol monophosphates whereas C3 was at least 1,000-fold less potent (Fig. 1d,f) .
In addition to signaling through heterotrimeric G proteins, hFFA2 can recruit arrestin adapter proteins 23, 24 . C3, but not SA, was able to promote interactions between wild-type hFFA2 and β-arrestin-2 in a concentration-dependent manner ( Supplementary  Fig. 2a ), while the opposite pattern of ligand-induced engagement was observed for interactions between hFFA2-DREADD and β-arrestin-2 ( Supplementary Fig. 2b ). These studies markedly expanded the previously reported high selectivity of SA for hFFA2-DREADD and lack of activity of this ligand at wild-type hFFA2 16 . hFFA2 antagonists inhibit hFFA2-DREADD activity. Two classes of high affinity synthetic FFA2 antagonists have been described 6, 7 . Exemplars from both series, including CATPB ((S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic acid) 18 and GLPG0974 (ref. 20 ), display high affinity at hFFA2 but not at rodent orthologs of FFA2(refs. [6] [7] [8] ). Here, we assessed whether the ability of both CATPB and GLPG0974 to block wild-type hFFA2 was preserved for hFFA2-DREADD. hFFA2 binds [ Table 1 ). Both antagonists were also able to inhibit, in a concentrationdependent fashion, recruitment of β-arrestin-2 to the appropriate receptor variants induced by EC 80 concentrations of either C3 or SA ( Supplementary Fig. 3d ,e and Supplementary Table 1 ).
Generation and characterization of hFFA2-DREADD-HA mice. CRE-loxP technology was next employed to generate transgenic knock-in mouse lines in which a section of exon 5 of the Ffar2 gene, containing the coding sequence for the mouse receptor, was replaced by sequences encoding for hFFA2-DREADD. Furthermore, a loxP-STOP-loxP cassette was placed upstream of the receptor coding sequences while the receptor sequence was appended with an in-frame, C terminal hemaglutinin (HA) epitope tag. Keeping the loxP-STOP-loxP cassette intact generated a strain that should express neither the wild-type receptor nor the hFFA2-DREADD-HA receptor. Effectively, this strain is an FFA2-knockout line, which we term 'MINUS-CRE' here. By crossing the MINUS-CRE strain with a whole body CRE-recombinase expressing strain, we generated mice where expression of hFFA2-DREADD-HA was driven from the endogenous mouse Ffar2 promoter. Under these conditions hFFA2-DREADD-HA receptor should be expressed in cell types and at levels equivalent to wild-type mouse FFA2, this mouse strain is termed hFFA2-DREADD-HA ( Supplementary  Fig. 4 and see Methods).
Animals were genotyped on the basis of the presence of the inserted transgene, while direct sequencing of the transgene validated the presence of the DREADD mutations and HA-epitope tag sequence (Methods). Quantitative PCR with reverse transcription (qRT-PCR) performed using mouse FFA2- (Fig. 2a) or hFFA2-DREADD-HA- (Fig. 2b ) specific primers indicated that corresponding transcripts showed quantitatively similar patterns of expression between wild-type C57BL/6 mice and homozygous hFFA2-DREADD-HA expressing animals in a selection of tissues known to express FFA2 (white adipose tissue, colon, lung) but to be lacking in other tissues (liver and cortex) (Fig. 2a,b) . Moreover, as anticipated from the genetic design, transcripts corresponding to hFFA2-DREADD-HA were not detected in tissues from the MINUS-CRE strain of mice ( . However, we confirmed that mRNA encoding FFA3 was expressed equally in colonic tissue of C57BL/6, MINUS-CRE and homozygous hFFA2-DRE-ADD-HA expressing mice (Fig. 2d) .
Previous studies from our laboratory 26 and others [27] [28] [29] have suggested a role for FFA2 in the release of the incretin GLP-1 from colonic crypts. Examination of the expression of hFFA2-DREADD-HA in the colon illustrated sparse expression inside subsets of enteroendocrine cells of the colonic crypts ( Fig. 3) as determined by co-staining of the HA-tagged hFFA2-DREADD with chromogranin A, a broad-spectrum marker for enteroendocrine cells, particularly monoamine-storing enteroendocrine cells 30 . By contrast, specific HA-immunostaining was not detected in equivalent sections from either C57BL/6 (Fig. 3) or the MINUS-CRE mice ( Supplementary Fig. 5a ). Expression of hFFA2-DREADD-HA was also detected in a broader range of cells. For example, clusters of submucosal cells in the duodenum were observed that were not co-stained with chromogranin A, indicating that they were distinct from entroendocrine cells and probably represent submucosal leukocytes ( Supplementary Fig. 5b ). These cell clusters also could not be observed in equivalent sections from either C57BL/6 or the MINUS-CRE mice ( Supplementary Fig. 5b ).
hFFA2-DREADD-HA releases GLP-1 from colonic crypts. We next examined release of GLP-1 from isolated colonic crypt-containing preparations. These preparations responded to the cAMP phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) with an approximately five-fold increase in release of GLP-1 over basal levels (Fig. 4a) . The extent of IBMX response was equivalent in crypt preparations derived from each of C57BL/6, hFFA2-DREADD-HA and the MINUS-CRE mice (Fig. 4a) . As anticipated from previous work 26, 28 , C3 also promoted GLP-1 release from colonic crypts derived from C57BL/6 mice ( Fig. 4b ), but SA did not (Fig. 4b) . By contrast, SA specifically promoted the release of GLP-1 from colonic crypts derived from hFFA2-DREADD-HA mice (Fig. 4c ) while C3 did not. Neither C3 nor SA was effective in preparations derived from the MINUS-CRE mouse strain (Fig. 4d) . These studies provided evidence that FFA2 mediates GLP-1 release from mouse colonic crypts. However, to confirm the effects of SA in tissues from the hFFA2-DREADD-HA expressing mice were not the result of undefined 'off-target' effects of SA, we employed the structurally distinct, human selective, FFA2 antagonists CATPB and Results are presented relative to the effect of IBMX (100 μM). e,f, The ability of CATPB (e) and GLPG0974 (f) to inhibit GLP-1 secretion induced by SA (e,f) in colonic crypts derived from hFFA2-DREADD-HA expressing mice is shown (e,f). Data represent the mean ± s.e.m. (n = 3-5). ***P < 0.001, two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test (a). *P < 0.05, **P < 0.01, ***P < 0.001, for significance versus vehicle data; $$$ P < 0.001, one-way ANOVA followed by Bonferroni post hoc test (b-f). g,h, Intact colonic preparations from C57BL/6 (g) or hFFA2-DREADD-HA (h) mice were mounted in a tissue chamber and following perfusion with buffer alone, either C3 (10 mM) (g) or SA (1 mM) (h, circles) was perfused at the time indicated by the arrow. GLPG0974 (10 μM) was perfused for 15 min before addition of SA and maintained throughout the exposure to SA (h, squares). Data represent the mean ± s.e.m. (n = 3-4). *P < 0.05, **P < 0.01, for significance versus vehicle (mean between values measured at 5, 10 and 15 min); one-way ANOVA followed by Bonferroni post hoc test (g,h). GLPG0974 to potentially block the effects of SA. Although neither CATPB nor GLPG0974 affected basal GLP-1 secretion when added alone (Fig. 4e,f) , both effectively blocked the release of the incretin produced by SA in tissue derived from hFFA2-DREADD-HA mice (Figs. 4e,f) . By contrast, no effect of either antagonist was observed on C3-mediated GLP-1 release from wild-type C57BL/6 mice ( Supplementary Fig. 6 ). Sections of the colon from either C57BL/6 or hFFA2-DREADD-HA mice were next introduced into a tissue bath. Following initial flow of buffer through the lumen of the colon to establish baseline GLP-1 release, C3 was added to preparations from C57BL/6 mice ( Fig. 4g) while SA was added to preparations from hFFA2-DREADD-HA expressing mice (Fig. 4h) . Each agonist markedly enhanced release of GLP-1 from the expected mouse line within the first sampling period and this was maintained for at least 20 min (Fig. 4g,h ). For hFFA2-DREADD-HA this was clearly an 'on-target' FFA2-mediated effect of SA because pre-treatment with, and the maintained presence of, GLPG0974 completely prevented response to SA (Fig. 4h) . Although it can be anticipated from these results that the effect of C3 in colonic tissue from wild-type C57BL/6 mice is also via FFA2, this could not be assessed directly because GLPG0974 does not have significant affinity at mouse FFA2.
FFA2 and the regulation of lipolysis.
To explore FFA2-mediated function in epididymal fat tissue, adipocytes were isolated from each of C57BL/6, hFFA2-DREADD-HA or MINUS-CRE mice, maintained in culture and allowed to differentiate for 8 days 26 . Oil Red O staining indicated equivalent lipid accumulation in cells derived from each mouse strain (Fig. 5a) . Furthermore, the β-adrenoceptor agonist isoproterenol induced lipolysis to a similar extent and with equivalent potency in adipocytes derived from each strain (Fig. 5b) . In tests of FFA2 function adipocytes from C57BL/6 mice treated with C3 showed a significant reduction in isoproterenol-stimulated lipolysis (Fig. 5c) whereas SA was without effect (Fig. 5c ). By contrast, an anti-lipolytic effect was produced by SA and not by C3 in adipocytes from hFFA2-DREADD-HA expressing mice (Fig. 5d) , while neither C3 nor SA was able to produce an anti-lipolytic effect in adipocytes derived from the MINUS-CRE line (Fig. 5e) . The effect of SA in adipocytes derived from hFFA2-DREADD-HA expressing mice was, moreover, concentration-dependent with log of the concentration of ligand required to inhibit an effect by 50% of the maximum (pIC 50 ) = 4.63 ± 0.18 ( Supplementary Fig. 7) . Consistent with the lack of activity of the human selective antagonists (n = 6-12). **P < 0.01, ****P < 0.0001, two-tailed t-test (a,c); one-way ANOVA followed by Bonferroni post hoc test (b). d-e, In vivo gastrointestinal transit was assessed in either C57BL/6 (d) or hFFA2-DREADD-HA (e) mice that were provided with free access to water, C3 (150 mM) or SA (15 mM) for 4 days after an initial acclimatization phase. On the final day, mice were gavaged and gastrointestinal (GI) transit was measured. Data represent the mean ± s.e.m. (n = 4-7). Significant reduction of gastrointestinal transit time was observed in C57BL/6 with C3 (d) and in hFFA2-DREADD-HA with SA (15 mM) (e). *P < 0.05, ***P < 0.001 (one-way ANOVA followed by Bonferroni post-test for multiple comparisons (d) and two-tailed t-test (e)). Note: the data presented in this d and e are the cumulative data of the individual mice that are presented in Supplementary Fig. 10 .
CATPB and GLPG0974 at mouse FFA2, neither of these agents was able to block C3-mediated anti-lipolytic effects in adipocytes derived from wild-type C57BL/6 mice ( Supplementary Fig 8a,b) . In contrast, both of these ligands, although without effect on lipolysis when added alone, effectively blocked the action of SA in adipocytes from hFFA2-DREADD-HA mice and, in each case, in a concentration-dependent manner (Figs. 5f,g ).
To assess the contribution of different G protein sub-groups to the physiological end points transduced by hFFA2-DREADD-HA we pretreated isolated and cultured adipocytes with either pertussis toxin, which blocks G i -mediated receptor signaling, or with FR900359 that blocks signaling via G q -family G proteins 26 . Antilipolytic effects of SA were blocked fully by pre-treatment with pertussis toxin but unaffected by pre-treatment with FR900359 ( Supplementary Fig. 9a ) demonstrating this to be a G i -mediated effect. By contrast, in colonic tissue SA-mediated release of GLP-1 was fully prevented by pre-treatment with FR900359 ( Supplementary Fig. 9b) while not affected by pertussis toxin, indicating that GLP-1 release is via a G q protein.
An in vivo role for FFA2 in GLP-1 release and gut transit.
To determine whether SA can act on hFFA2-DREADD in vivo we adapted methods that describe the release of GLP-1 into the portal vein of mice following intra-colonic administered C3 31 . We confirmed that C3 (150 mM) administered into the colon of wild-type animals resulted in significant increase in GLP-1 plasma levels in the portal vein, a response that was completely absent in control MINUS-CRE mice (Fig. 6a,b) . Intra-colonic administration of SA generated a similar increase in portal vein GLP-1 plasma levels when administered to hFFA2-DREADD-HA mice (Fig. 6c) . No response to SA was measured in MINUS-CRE control animals (Fig. 6b) , demonstrating that in the hFFA2-DREADD-HA mice SA was operating via the hFFA2-DREADD receptor and that the response to SA mimicked the response seen for C3 at FFA2 in the wild-type mice.
In a second test of the in vivo response of SA at hFFA2-DREADD, we examined the potential role of FFA2 in gut transit. Previous in vivo studies had indicated that administration of SCFAs into the gut (gavage) accelerated gut transit 32 . However, a more recent ex vivo study on isolated colon showed the opposite, where C3, possibly acting via FFA2, decreased gut transit 33 . We resolved this issue using the hFFA2-DREADD-HA mice. Administration of C3 in the drinking water of wild-type mice accelerated gut transit while SA had no effect (Fig. 6d and Supplementary Fig. 10a-c) . In contrast, SA stimulated a significant increase in gut transit in hFFA2-DREADD-HA mice (Fig. 6e and Supplementary Fig. 10d,e) . This not only demonstrated unequivocally that SA activates the hFFA2-DREADD receptor in vivo, but also that FFA2 activation mediates an increase in gut transit.
Discussion
GPCRs remain the most highly studied group of therapeutic drug targets and many ligands that modulate GPCR function are continuing to gain regulatory approval 34 . As such, finding novel ligands or re-purposing previously identified ones is integral to efforts to understand the biology and therapeutic potential, particularly of poorly studied GPCRs 35, 36 . This has been approached by methods ranging from high throughput and virtual screening to the application of structure-based drug design. However, finding ligands that are highly selective between closely related GPCRs that can be used to define novel biology and in target validation remains a substantial challenge and a major barrier to advances in pharmacology and drug discovery. Here, we have endeavored to address this final issue by employing a DREADD receptor mutant to assess two fundamental questions; (1) can a DREADD mutant be used to distinguish the biological action of the target receptor from other closely related receptors (for example, FFA2 versus FFA3)? And (2), can this approach give insights into the action of selective pharmacological ligands at the target receptor in a way that can be used in target validation and drug design?
Our study is a substantial departure from the more common uses of DREADDs (particularly muscarinic acetylcholine DREADDs) that have largely been to determine the importance of particular down-stream signaling pathways in physiological responses [12] [13] [14] [15] and to link receptor activation to behavioral phenotypes 37 . In contrast, we have employed here a hFFA2-DREADD, knocked into the mouse Ffar2 gene locus in a manner that replaces the wild-type receptor with a DREADD mutant activated by the otherwise inert synthetic molecule SA with the aim of defining specific functions of this receptor. Such DREADD-knock-in mice were untested as a strategy to probe the biological function of selected target receptors.
We illustrate here that signaling through hFFA2-DREADD is indistinguishable from that of wild-type hFFA2. Thus, SA promoted interactions of hFFA2-DREADD with the same panoply of G proteins as did the SCFA, propionate, via wild-type hFFA2. More specifically, coupling of hFFA2-DREADD to down-stream signaling pathways mediated by G q and G i family G proteins, as well as interactions with β-arrestin-2 were equivalent to the wild-type receptor. As such, activation of hFFA2-DREADD with SA faithfully reproduces the signaling repertoire produced by SCFAs when activating FFA2. This key proof-of-principle provided confidence that SA acting at hFFA2-DREADD-HA in tissues from knock-in mice would act as an appropriate molecular probe to define biological roles of FFA2. Given that mFFA2 and the hFFA2-DREADD variant are able to interact with a wide range of G proteins, it will be interesting to explore the contribution of these to distinct physiological outcomes in these animals.
Because the hFFA2-DREADD variant displayed near equivalent signaling to the wild-type hFFA2 receptor, we proceeded to generate a knock-in mouse line expressing hFFA2-DREADD-HA in place of the wild-type receptor. In this engineered line the tissue expression of hFFA2-DREADD-HA was the same as mFFA2, providing confidence that our model would faithfully reflect mFFA2 function and by inference possibly that of FFA2 in humans.
The first expectation of hFFA2-DREADD-HA knock-in mice was that responses to SCFAs would be lost because in vitro experiments demonstrated that this mutant receptor was unresponsive to SCFAs. In this way, the hFFA2-DREADD-HA knock-in mice were expected to mimic FFA2-knockout mice (represented here by the MINUS-CRE control strain). This indeed was proved to be the case as the previously defined anti-lipolytic response to the SCFA C3 in isolated adipocytes, and the induction of GLP-1 release from colonic crypts, was lacking in the MINUS-CRE mice preparations. Moreover, because expression of FFA3 in the knockin mouse line was unaffected, the complete lack of response to SCFAs in these two tissue models also infers a lack of contribution of FFA3. This conclusion had previously been uncertain. FFA3 has been shown to be expressed by many enteroendocrine cells inside the colon 28 and these same authors suggested that a poorly characterized, potentially FFA3 receptor-selective, activator can promote GLP-1 release 28 more effectively than activation of FFA2. Moreover, studies by Tolhust et al. 27 had indicated that SCFAmediated secretion of GLP-1 was compromised in both Ffar2 and Ffar3 whole-body knockout mice. Our results instead show this effect to be mediated entirely by FFA2. As well as the stimulatory effect of the FFA2-DREADD agonist SA in tissue isolated from mice expressing hFFA2-DREADD-HA, this conclusion is further supported because the effect of SA can be defined unambiguously as being 'on-target' as it was completely blocked by exemplar compounds from two chemically distinct classes of human FFA2 specific antagonists that retain high affinity at hFFA2-DREADD. The complete selectivity of the antagonists CATPB and GLPG0974 for the human ortholog of FFA2 was also useful in that neither of these had any effect, either directly when added alone or in capacity to block the effects of C3, in tissues from wild-type mice. This contrasts with the muscarinic acetylcholine receptor DREADDs where standard antagonists such as atropine maintain high affinity at the modified receptor and also still bind to and block all subtypes of the muscarinic receptor family 10 . The capacity here to define effects of SA as 'on-target' or 'off-target' is particularly attractive because small molecule ligands with modest potency at the 'on-target' site are frequently pleiotropic in actions and it is well established that SCFAs can, for example, also act as epigenetic regulators. Indeed, in a recent study using isolated perfused rat colon as a model of colonic endocrine secretion, Christiansen et al. suggested that effects of SCFAs on release of GLP-1 were not mediated by either FFA2 or FFA3 38 . As a number of other GPCRs are known to have antagonist ligands that are highly speciesortholog selective, then the proof-of-concept developed here may well be appropriate to define both 'on-target' and 'off-target' effects of activators of other poorly characterized GPCRs by developing equivalent transgenic mouse lines.
A role of FFA2 in GLP-1 release from enteroendocrine cells was further supported by our in vivo studies where GLP-1 levels in the portal vein were seen to be increased following intra-colonic administration of SA in hFFA2-DREADD mice. Such a response was not produced in control mice. This not only confirmed a role for FFA2 in the regulation of GLP-1 release from the gut, but it also established the general use of the DREADD-model to study the biology of FFA2 in live animals. This general principle was further extended by investigation of a potential role of FFA2 in the regulation of gut transit. Earlier in vitro and in vivo studies reported conflicting findings where SFCAs, possibly acting at FFA2, regulated gut transit either in a positive 32 or negative 33 manner. By administration of SA in the drinking water we were able to resolve these contradictory studies by showing that SA accelerated gut transit in a manner that was completely dependent on the expression of the hFFA2-DREADD-HA receptor.
Although less contentious in terms of the identity of the receptor(s) involved [39] [40] [41] , equivalent studies with tissue from the knock-in mouse lines also provided unequivocal evidence that FFA2 is the receptor responsible for SCFA-mediated anti-lipolytic responses in white fat epididymal cells. Our previous studies established that SCFAs mediate anti-lipolytic effects through G i -signaling and GLP-1 release through G q / 11 -signaling 26 . Linking these previous findings with the current studies determines that these physiological effects of SCFAs are both mediated via FFA2 and we can conclude that FFA2 recruits distinct G proteins in a tissue-dependent fashion to drive specific physiological responses 26 . The promiscuous G-protein-coupling capability of FFA2 that has also been observed in previous in vitro studies 21 may therefore illustrate a natural flexibility to recruit different G proteins to drive selected physiological responses in different settings.
In our study, we have not only used hFFA2-DREADD to define novel biology of FFA2, but we have also provided evidence for the general application of other DREADD-knock-in mice to define the function of GPCRs for which selective ligands are not available. This approach also provides a means of testing the physiological roles and potential therapeutic outcomes of selectively activating the target GPCR. In this way, using FFA2 as an exemplar receptor, we have illustrated the broader potential of this approach to investigate both GPCR biology and drug target validation.
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. Briefly, tissues from colon, adipose, liver, lung and cortex were collected from C57BL/6 and hFFA2-DREADD-HA animals and quickly frozen on dry ice and stored at −80 °C until processing. For the nucleic acid isolation, samples were defrosted on ice and immediately digested for 10 min at 50 Hz in TissueLyser LT (Qiagen) in the presence of RLT Plus buffer (Qiagen) and two metallic beads (Qiagen). RNA was isolated from digested material using RNeasy Mini Kit (Qiagen) as per the manufacturer's instructions. The eluted RNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific) and the RNA quality was assessed by running 500 ng of RNA on 1% agarose gel.
After quantification, 1 µg of RNA was retro-transcribed to complimentary DNA using QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer's instructions. Then, qRT-PCR was performed with 33 ng of cDNA sample using Fast SYBR Green Master Mix (Thermo Scientific) as per the manufacturer's instructions. Primers were as follows: Ffar2, ggtgggcactgagaaccaaa (sense) and ccacacgaagcgccaataac (antisense); hFFA2-DREADD-HA, gtgtgggtcaaggagaagggatg (sense) and gcgtaatctggaacatcgtacgg (antisense); β-actin (reference gene), gacaggatgcagaaggagattactg (sense) and ctcaggaggagcaatgatcttgat (antisense). For Ffar3 amplification, qRT-PCR was performed with 33 ng of cDNA sample in the presence of TaqMan Gene Expression Master Mix (Thermo Scientific) using Ffar3 and GAPDH (reference gene) hydrolysis probes (Mm02621638_s1 and Mm99999915_g1, respectively; Thermo Scientific). Amplification reactions were obtained using QuantStudio 7 Flex Real-Time PCR System (Thermo Scientific). The qRT-PCR data, where reported, are presented as 1/ΔCt (where ΔCt is the difference between the amplification cycles of the target gene and the reference gene).
Plasmids. Human FFA2 and FFA2-DREADD receptors in expression vector pcDNA5 frt were modified so that an HA tag sequence YPYDVPDYA was added to the N or C terminus. To generate C-terminal eYFP fusions, FFA2 or FFA2-DREADD were cloned in-frame and upstream of eYFP in expression vector pcDNA5 frt. The GRK2 BRET biosensor was constructed in lentiviral expression vector pLVX IRES, a polycistronic vector expressing GRK2 fused at its C terminus to GFP 10 , unmodified G protein β subunit 1 and G protein γ subunit 5 fused at its N terminus to Rluc II. Wild-type G α subunits were obtained from cdna.org in expression vector pCDNA3.1. All constructs were verified by DNA sequencing.
BRET assay to assess GPCR-G protein interaction based on GRK2 interaction with G protein βγ-subunits. A BRET-based biosensor was used to assess the G-protein-coupling profile of FFA2 or FFA2-DREADD. The sensor exploits the ability of GRK2 to interact with G protein βγ subunits following receptor activation 22 . This enables the G protein activation profile of a GPCR to be established using the same BRET partners without the need to modify either the Gα subunit or the receptor of interest. HEK293 cells were seeded into six-well plates at 5 × 10 5 cells per well and allowed to settle. Cells were then co-transfected with 200 ng of receptor, 200 ng of polycistronic GRK2 biosensor and 300 ngG protein α subunit. Transfections were performed using PEI at a ratio of 3 μg PEI to 1 μg DNA. Twenty-four hours after transfection, cells were detached using PBS containing 1 mM EDTA and distributed into poly-d-lysine-coated white 96-well microplates and incubated for a further 24 h before the assay. Cells were then washed with and incubated in Hanks' balanced salt solution for 1 h at 37 °C. To initiate the assay, Coelenterazine 400a (Nanolight Technology) was added (2.5 μM) and incubated for 5 min; cells were then stimulated with C3 or sorbic acid (10 mM) for 10 min before emissions at 400 nm and 510 nm were measured using a Tristar LB 941 multimode plate reader (Berthold Technologies) equipped with a bioluminescence resonance energy transfer 2 (BRET 2 ) filter set (400 ± 70 nm and 515 ± 20 nm filters). The BRET signal was represented as the 510:400 ratio. The fold increase in BRET signal for each G protein α subunit was determined by dividing the signal obtained by the addition of ligand by the values obtained from the addition of only the vehicle.
G protein α subunit tagged with Renilla luciferase and the G protein γ1 subunit sensors. Experiments were performed using the same procedure as the one described above for the GRK2 biosensor assay. Cells were co-transfected with 200 ng of plasmid DNA encoding hFFA2, hFFA2-DREADD or the human M 3 muscarinic acetylcholine receptor, plus 200 ng of plasmid DNA encoding Rluc II Gα-subunit, plus 100 ng of plasmid DNA encoding Gβ1 and 200 ng GFP10-Gγ1 subunits. The ligand-induced change in BRET was determined by subtracting the signal obtained by the addition of vehicle from the values obtained by the addition of ligand.
Cell lines. HEK-293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) without sodium pyruvate, supplemented with 10% (v/v) fetal bovine serum and penicillin/streptomycin mixture (Sigma-Aldrich) in a humidified atmosphere containing 5% CO 2 at 37 °C. For experiments using transiently transfected HEK-293T cells, transfections were carried out using PEI and experiments were conducted 48 h post-transfection. In experiments using stably expressing cells, all transformed cell lines were derived from Flp-In T-REx 293 cells and were designed to express the desired receptor, either hFFA2 or hFFA2-DREADD, on demand following induction with the antibiotic doxycycline (100 ng ml −1 , ref. 26 ). In all cases, the receptor construct expressed was fused inframe to enhanced yellow fluorescent protein (eYFP) at its C terminal. cAMP assays. cAMP accumulation was tested using a homogeneous time-resolved fluorescence (HTRF) cAMP dynamic kit (CisBio Bioassays, CisBio) as previously described 26 . Briefly, cells were plated at the density of 2,000 cells per well in lowvolume 384-well plates in the presence of 500 µM IBMX and test compounds, and incubated for 15 min at room temperature. After this time, 10 nM or 1 μM forskolin was added to hFFA2 or hFFA2-DREADD-expressing cells, respectively, and further incubated for 30 min at room temperature. Reactions were stopped according to the manufacturer's instructions and outputs were measured using a PHERAstar FS plate reader (BMG Labtech).
IP1 accumulation assays.
Assays were performed using a HTRF IP1 dynamic kit (CisBio Bioassays) as previously described 26 . β-Arrestin-2 recruitment assay. β-Arrestin-2 recruitment to a receptor of interest was assessed using a bioluminescence resonance energy transfer (BRET)-based approach, employing either hFFA2 or hFFA2-DREADD constructs fused at their C termini with eYFP 16 . Briefly, the eYFP tagged receptor construct to be assayed was co-transfected into HEK-293T cells using PEI in a 4:1 ratio with a plasmid encoding β-arrestin-2 fused at its N terminal to NanoLuc luciferase. Subsequent experimental procedures were performed as previously described 16 . The final concentration of Coelenterazine-h used was 2.5 μM. BRET between NanoLuc luciferase and eYFP, resulting from interactions between the FFA2 and β-arrestin-2 constructs, was assessed by measuring the ratio of luminescence at 535 and 475 nm using a PHERAstar FS plate reader. For experiments testing hFFA2 antagonists, the antagonist test compound (or appropriate vehicle) was pre-incubated with the cells 15 min before the addition of agonist. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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